Immunitybio announces collaboration with beigene on confirmatory phase 3 trial of anktiva® and pd-1 checkpoint inhibitor combination in non-small cell lung cancer

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx) today announced it has entered into a collaboration and supply agreement with beigene, ltd. (to be changed to beone medicines, ltd.), a global oncology company, to conduct a confirmatory randomized phase 3 clinical trial (resq201a-nsclc), combining beigene's tislelizumab, a pd-1 checkpoint inhibitor (cpi), and immunitybio's anktiva (nogapendekin alfa inbakicept-pmln). the phase 3 resq201a-nsclc study (nct06745908) aims to co.
IBRX Ratings Summary
IBRX Quant Ranking